199 related articles for article (PubMed ID: 17157933)
1. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
Lindgren HS; Rylander D; Ohlin KE; Lundblad M; Cenci MA
Behav Brain Res; 2007 Feb; 177(1):150-9. PubMed ID: 17157933
[TBL] [Abstract][Full Text] [Related]
2. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
3. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Mela F; Millan MJ; Brocco M; Morari M
Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
[TBL] [Abstract][Full Text] [Related]
4. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
5. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Lane EL; Cheetham SC; Jenner P
Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
[TBL] [Abstract][Full Text] [Related]
6. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Eskow KL; Gupta V; Alam S; Park JY; Bishop C
Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
[TBL] [Abstract][Full Text] [Related]
7. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
8. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
11. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
[TBL] [Abstract][Full Text] [Related]
12. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats.
Papathanou M; Rose S; McCreary A; Jenner P
Eur J Neurosci; 2011 Jun; 33(12):2247-54. PubMed ID: 21615558
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Ferger B
Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
[TBL] [Abstract][Full Text] [Related]
14. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2007 Jan; 25(1):259-69. PubMed ID: 17241287
[TBL] [Abstract][Full Text] [Related]
15. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
Carta AR; Tronci E; Pinna A; Morelli M
Eur J Neurosci; 2005 Mar; 21(5):1196-204. PubMed ID: 15813929
[TBL] [Abstract][Full Text] [Related]
16. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
17. Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Valastro B; Dekundy A; Danysz W; Quack G
Behav Brain Res; 2009 Jan; 197(1):90-6. PubMed ID: 18762218
[TBL] [Abstract][Full Text] [Related]
18. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Lane EL; Cheetham SC; Jenner P
Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
[TBL] [Abstract][Full Text] [Related]
19. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
[TBL] [Abstract][Full Text] [Related]
20. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]